<DOC>
	<DOC>NCT02227173</DOC>
	<brief_summary>This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.</brief_summary>
	<brief_title>A Phase 1 Drug-drug Interaction Study in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive, with a body mass index of 18.0 to 32.0 kg/m2, inclusive Women of childbearing potential must agree to follow instructions for methods of contraception for the duration of the study Any significant acute or chronic medical illness History of arrhythmias or palpitations associated with dizziness or fainting History of clinically relevant cardiac disease Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>